Associated Papers
ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?
Bruckmueller H et al.
Expert Opinion on Drug Metabolism & Toxicology, 2021
Polymorphisms of genes encoding drug transporters or cytochrome P450 enzymes and association with clinical response in cancer patients: a systematic review.
Kulma I et al.
Cancer Chemotherapy and Pharmacology, 2019
Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy.
Rodieux F et al.
Journal of Clinical Pharmacology, 2016
Multidrug resistance gene (MDR1) polymorphisms may not be directly associated with response to imatinib in chronic myeloid leukemia.
Wang JL et al.
Genetics and Molecular Research : Gmr, 2015
Genotype variability and haplotype profile of ABCB1 (MDR1) gene polymorphisms in Macedonian population.
Naumovska Z et al.
Prilozi (makedonska Akademija Na Naukite I Umetnostite. Oddelenie Za Medicinski Nauki), 2014
Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study.
Caronia D et al.
Plos One, 2011
Implications of genetic polymorphisms in drug transporters for pharmacotherapy.
Kerb R
Cancer Letters, 2006
Predicting drug response and toxicity based on gene polymorphisms.
Robert J et al.
Critical Reviews in Oncology/hematology, 2005
Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.
Lötsch J et al.
Clinical Pharmacokinetics, 2004
MDR1 genotype-related pharmacokinetics and pharmacodynamics.
Sakaeda T et al.
Biological & Pharmaceutical Bulletin, 2002
Select a paper to view details